Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm TaiwanTPE:1789 -1.80%82 Return-on-Tangible-Asset is 0.56% as of Mar. 2026, which is 79% below its 10-year median of 2.65. GuruFocus rates TPE:1789 with a GF Score™ of 82/100 and a GF Value™ of NT$25.00 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 60.52% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Scinopharm Taiwan's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$66 Mil. Scinopharm Taiwan's average total tangible assets for the quarter that ended in Mar. 2026 was NT$11,844 Mil. Therefore, Scinopharm Taiwan's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.56%.
The historical rank and industry rank for Scinopharm Taiwan's Return-on-Tangible-Asset or its related term are showing as below:
TPE:1789'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.9 Med: 2.65 Max: 5.28
Current: 0.9
During the past 13 years, Scinopharm Taiwan's highest Return-on-Tangible-Asset was 5.28%. The lowest was 0.90%. And the median was 2.65%.
TPE:1789's Return-on-Tangible-Asset is ranked worse than 60.52% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.12
vs TPE:1789: 0.90
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Scinopharm Taiwan Return-on-Tangible-Asset Related Terms
Scinopharm Taiwan Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1789 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.56% mean?
Scinopharm Taiwan (TPE:1789) has a Return-on-Tangible-Asset of 0.56% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Scinopharm Taiwan and its competitors. This is 79% below median its historical median of 2.65. Over the past decade, Scinopharm Taiwan's Return-on-Tangible-Asset has ranged from 0.90 to 5.28. According to the industry distribution chart, Scinopharm Taiwan ranks #610 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 60.5%.
Is Scinopharm Taiwan's Return-on-Tangible-Asset too high?
Scinopharm Taiwan's current Return-on-Tangible-Asset of 0.56% is 79% below median its 10-year median of 2.65. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 5.28. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.12. Scinopharm Taiwan's value of 0.56% is 82.1% below this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #610 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #610 out of 1008 companies for Return-on-Tangible-Asset. This places Scinopharm Taiwan in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.12. Scinopharm Taiwan's value of 0.56% is 82.1% below this benchmark. Historically, Scinopharm Taiwan's own Return-on-Tangible-Asset has ranged from 0.90 to 5.28 over the past decade. While the company's 10-year median is 2.65 vs. the industry median of 3.12, Scinopharm Taiwan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.12, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current Return-on-Tangible-Asset of 0.56% is 82.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Return-on-Tangible-Asset is 0.56%, which is 79% below median its own 10-year median of 2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$25.00, compared to a current price of NT$19.10 — trading 23.6% below its estimated fair value. The current Return-on-Tangible-Asset is 0.56%, which is 79% below median its 10-year median of 2.65 and 82.1% below the Drug Manufacturers industry median of 3.12. Scinopharm Taiwan's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Return-on-Tangible-Asset is 0.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.10 is trading 23.6% below its estimated GF Value™ of NT$25.00.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Return-on-Tangible-Asset: 0.56% (79% below median its 10-year median of 2.65)
GF Value™: NT$25.00 vs. price of NT$19.10 (23.6% below fair value)
Industry Position: 82.1% below the Drug Manufacturers median (#610 of 1008)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
82GF Score
Get the complete analysis for TPE:1789
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
